[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Polynovo Ltd (PNV.AX)

Polynovo Ltd (PNV.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Polynovo Ltd 320 Lorimer Street Unit 2 Port Melbourne VIC 3207 AUS

https://www.polynovo.com P: +61 386814050 F: +61 386814099

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

Key Statistics

Overview:

Market Capitalization, $K 832,466
Shares Outstanding, K 690,843
% of Institutional Shareholders 20.06%

Financials:

Annual Sales, $ 127,243 K
Annual Net Income, $ 13,214 K

Growth:

1-Year Return -2.71%
3-Year Return -19.40%
5-Year Return -55.04%
5-Year Revenue Growth 41.85%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm 0.01
EPS Growth vs. Prev Year 1.52%
Dividend Payout Ratio 0.00%
Most Recent Split 0-1 on 05/03/04

PNV.AX Ratios

Ratio
Price/Earnings ttm 85.46
Price/Earnings forward 40.49
Return-on-Equity % 12.45%
Return-on-Assets % 8.37%
Profit Margin % 10.38%
Debt/Equity 0.18
Price/Sales 6.11
Price/Book 10.01
Book Value/Share 0.12
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.